Jyong Biotech Ltd. Ordinary Shares
MENSHealthcare|Biotechnology|TW
$1.80
+0.15 (+9.09%)
Cash / Share
$0.02
Financials
Financial Snapshot
Market Cap
$136.8M
Enterprise Value
$154.2M
Revenue (TTM)
$0.00
Net Income (TTM)
-$4.7M
Cash & Investments
$1.2M
Net Cash
-$17.4M
Free Cash Flow (TTM)
$0.00
Operating CF (TTM)
$0.00
Debt/Equity
-0.74
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $4.2M | $2.4M | $812.0K | $177.0K | $98.0K | $1.2M | $1.2M | |
| Operating Cash Flow | -$1.1M | -$2.0M | -$3.0M | -$2.6M | -$3.6M | -$3.0M | $0.00 | |
| Free Cash Flow | -$1.2M | -$2.1M | -$3.2M | -$2.6M | -$3.6M | -$3.0M | $0.00 | |
| Capital Expenditure | -$88.0K | -$137.0K | -$246.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $4.9M | -$1.4M | $3.3M | $2.0M | $2.0M | $17.6M | $0.00 |
R&D Spending
R&D (TTM)
$813.4K
R&D Intensity
—
R&D Growth vs Prior
+11.3%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $1.5M | $1.6M | $1.3M | $1.1M | $927.0K | $731.0K | $813.4K | |
| SG&A | $931.0K | $845.0K | $1.5M | $1.7M | $1.1M | $1.8M | $1.8M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $121.0K | $122.0K | $127.0K | $120.0K | $100.0K | $0.00 | |
| Gross Profit | $0.00 | -$121.0K | -$122.0K | -$127.0K | -$120.0K | -$100.0K | $0.00 | |
| R&D | $1.5M | $1.6M | $1.3M | $1.1M | $927.0K | $731.0K | $813.4K | |
| SG&A | $931.0K | $845.0K | $1.5M | $1.7M | $1.1M | $1.8M | $1.8M | |
| Operating Income | -$2.4M | -$2.4M | -$2.8M | -$2.8M | -$2.1M | -$2.6M | -$2.6M | |
| Interest Expense | $832.0K | $835.0K | $765.0K | $757.0K | $1.0M | $2.5M | $2.5M | |
| Pretax Income | -$1.9M | -$4.2M | -$6.6M | -$4.4M | -$3.0M | -$4.7M | -$4.7M | |
| Net Income | -$1.9M | -$4.2M | -$6.6M | -$4.4M | -$3.0M | -$4.7M | -$4.7M | |
| EPS (Diluted) | -0.03 | -0.06 | -0.09 | -0.06 | -0.04 | -0.06 | -0.10 | |
| EBITDA | -$2.3M | -$3.2M | -$5.7M | -$3.5M | -$1.9M | -$2.5M | -$2.6M | |
| Shares Out. (M) | 71.57 | 76.03 | 76.03 | 76.03 | 76.03 | 73.01 | 74.23 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.6M | $551.0K | $718.0K | $177.0K | $98.0K | $1.2M | $1.2M | |
| Short-Term Investments | $664.0K | $1.8M | $94.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $6.2M | $2.6M | $2.5M | $1.8M | $206.0K | $15.5M | $15.5M | |
| Total Assets | $12.8M | $9.4M | $8.7M | $8.2M | $6.4M | $20.8M | $20.8M | |
| Total Current Liabilities | $5.8M | $6.3M | $12.9M | $14.3M | $12.1M | $34.8M | $34.8M | |
| Long-Term Debt | $8.3M | $6.3M | $6.3M | $8.5M | $10.7M | $10.2M | $10.2M | |
| Total Liabilities | $32.0M | $32.8M | $38.4M | $42.3M | $42.9M | $45.7M | $45.7M | |
| Stockholders' Equity | -$19.2M | -$23.3M | -$29.6M | -$34.1M | -$36.5M | -$24.9M | -$24.9M | |
| Retained Earnings | -$14.8M | -$19.0M | -$25.7M | -$30.1M | -$33.1M | -$37.8M | -$37.8M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1M | -$2.0M | -$3.0M | -$2.6M | -$3.6M | -$3.0M | $0.00 | |
| Capital Expenditure | -$88.0K | -$137.0K | -$246.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$1.2M | -$2.1M | -$3.2M | -$2.6M | -$3.6M | -$3.0M | $0.00 | |
| Investing Cash Flow | $731.0K | -$1.3M | $1.4M | $95.0K | $0.00 | -$13.5M | $0.00 | |
| Financing Cash Flow | $4.9M | -$1.4M | $3.3M | $2.0M | $2.0M | $17.6M | $0.00 | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $17.8M | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $2.4M | -$1.3M | $3.6M | $2.5M | $2.2M | -$24.0K | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | $5.2M | -$4.6M | $1.7M | -$532.0K | -$1.6M | $1.1M | $1.0M |
Dilution Tracker
Shares Outstanding
76M
5-Year Share Growth
+2.0%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 71.57 | 76.03 | 76.03 | 76.03 | 76.03 | 73.01 | 74.23 | |
| Change vs Prior % | — | 6.2% | 0.0% | 0.0% | 0.0% | -4.0% | 1.7% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $17.8M | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| ROE % | 10.0% | 18.0% | 22.4% | 12.9% | 8.3% | 18.8% | 19.4% | |
| ROA % | -14.9% | -44.5% | -75.8% | -53.3% | -47.4% | -22.5% | -22.5% | |
| ROIC % | -20.3% | -28.9% | -77.4% | -133.7% | -122.4% | 46.0% | 46.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | -0.8% | -4.1% | 5.5% | 16.7% | |
| Operating Income | 0.0% | 1.7% | -17.7% | 1.1% | 26.5% | -26.8% | |
| Net Income | 0.0% | -119.1% | -57.9% | 33.6% | 31.4% | -54.7% | |
| EPS (Diluted) | 0.0% | -106.0% | -58.0% | 33.6% | 31.4% | -61.2% | |
| Operating Cash Flow | 0.0% | -82.5% | -49.7% | 12.5% | -39.3% | 16.1% | |
| Free Cash Flow | 0.0% | -80.5% | -51.7% | 19.1% | -39.3% | 16.1% | |
| R&D Expense | 0.0% | 2.9% | -17.3% | -17.0% | -13.4% | -21.1% | |
| SG&A Expense | 0.0% | -9.2% | 82.1% | 12.2% | -34.6% | 57.3% | |
| Total Assets | 0.0% | -26.6% | -7.3% | -5.7% | -22.8% | 226.4% | |
| Book Value / Share | 0.0% | -14.3% | -27.0% | -15.0% | -7.2% | 29.0% | |
| Debt | 0.0% | -13.3% | 20.9% | 17.1% | 8.7% | 2.3% | |
| Diluted Shares | 0.0% | 6.2% | 0.0% | 0.0% | 0.0% | -4.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-5.36
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.02
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -377.24 | -183.15 | -115.94 | -174.61 | -254.66 | -61.72 | -20.81 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -37.68 | -32.95 | -25.94 | -22.56 | -21.05 | -11.58 | -5.36 | |
| EV/EBITDA | -314.04 | -240.63 | -136.22 | -223.31 | -422.04 | -121.96 | -58.71 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-2.28
Distress
Piotroski F-Score
3
Weak